<DOC>
	<DOCNO>NCT00455091</DOCNO>
	<brief_summary>Research Objective Study End Points To evaluate anti-HBV well HCC recurrence reduce effect standard ( 18 month ) lamivudine treatment time HBV reactivation hepatitis flare ( HBV DNA &gt; 105 copies/mL ALT level &gt; 2.0 x UNL ) prophylactic , prolong ( 36 month ) adefovir dipivoxil therapy post-operative HBsAg ( + ) , &lt; 5 cm HCC patient , compare result group historical control ( T1297 , HBsAg+ , &lt; 5 cm HCC cohort ) , term follow endpoint . 1 . Primary endpoint : 3-years recurrence rate ( exclude recur within first year ) . 2 . Secondary endpoint : first 2 year tumor recurrence rate recurrence-free survival overall survival . anti-viral efficacy , i.e . biochemical response viral response rate . correlate change viral titer clinical outcome post- operative HCC patient adjuvant lamivudine adefovir therapy .</brief_summary>
	<brief_title>A Phase III Study Post-Operative HBV-Related Hepatocellular Carcinoma</brief_title>
	<detailed_description>Treatment plan Randomization scheme : HBsAg+ , HCC &lt; 5 cm curative resection Stratified HBV DNA &lt; 105 OR â‰¥ 105 copies/mL Genotype B C RANDOMIZATION Prophylactic group Therapeutic control group Adefovir Dipivoxil 10mg/day x 36 month Lamivudine 100 mg/day x 18 month # , HBV DNA =/ &gt; 105 copies/mL ALT &gt; 2.0 x UNL - When YMDD mutant present , switch Adefovir dipivoxil 10mg/day x 24 month . Selection patient 1 . Eligibility Criteria ( 1 ) Histologically proven hepatocellular carcinoma . ( 2 ) HCC underwent curative resection within 6 week registration . ( 3 ) Grossly , resection margin &gt; 1 cm . ( 4 ) Tumors , either single , &lt; 5 cm size 3 size &lt; 3 cm . ( 5 ) Patients must performance status ECOG score &lt; 2 . ( 6 ) Patients must adequate liver reservation adequate hemogram . ( ) Pugh-Child 's Score &lt; 7 . ( ii ) The serum total bilirubin level &lt; 2 mg/dl . ( iii ) The prothrombin time &lt; 3 sec normal control . ( iv ) The platelet &gt; 7.5 x 104 / mm3 . ( v ) The WBC &gt; 3,000 / mm3 . ( 7 ) Patient must serum creatinine &lt; 1.5 mg/dl ( 8 ) Cardiac function NYHA classification &lt; Grade II ( 9 ) HBsAg ( + ) . ( 10 ) Signed informed consent . 2 . Ineligibility Criteria 1 . Patients non-curative resection eligible . 2 . Resected HCCs histologically positive margin eligible . 3 . HCCs radiological evidence portal vein thrombus eligible . 4 . Patients systemic disease require concurrent usage glucoticosteroid immunosuppressant agent ( ) eligible . 5 . Patients advanced second primary malignancy eligible . 6 . Patients pregnancy breast-feeding eligible . 7 . Patients severe cardiopulmonary disease eligible . 8 . Patients clinically significant psychiatric disorder eligible . 9 . Patients antineoplastic chemotherapeutic immuno-therapeutic drug corticosteroid within 6 week commence protocol eligible . 10 . Patients prior lamividine and/or adefovir dipivoxil therapy eligible . 11 . Anti-HCV positive patient eligible . Statistical Consideration Sample size : With phase III superior study design , give 80 % power two-sided 5 % significance level , 139 patient per treatment arm include study . If 10 % drop-out rate include , totally , 309 patient ( 155 per study arm ) require . Analysis The objective follow : 1.Primary endpoint : 3-year recurrence rate ( exclude recur within 1st year ) 1 . Second endpoint recurrence-free survival . 2 . Second endpoint : overall survival . 3 . Second endpoint : anti-viral efficacy , term sustain biochemical response rate viral response rate . To correlate change viral titer clinical outcome 2 RFS OS compute date randomization . ( 1 ) In analysis RFS , patient die without disease recurrence censor recurrence date death ( 2 ) In analysis OS , event define death cause . ( 3 ) The survival distribution RFS OS estimate Kaplan Meier method . ( 4 ) Statistical comparison RFS OS two treatment arm perform log-rank test . ( 5 ) Cox proportional hazard model use assess importance potential prognostic factor , well test significance treatment adjust factor [ 39 ] . 3.Tumor size , Liver inflammation , viral status , i.e . HBV genotype DNA titer</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>1 . Histologically proven hepatocellular carcinoma . 2 . HCC underwent curative resection within 6 week registration . 3 . Grossly , resection margin &gt; 1 cm . 4 . Tumors , either single , &lt; 5 cm size 3 size &lt; 3 cm . 5 . Patients must performance status ECOG score &lt; 2 . 6 . Patients must adequate liver reservation adequate hemogram . PughChild 's Score &lt; 7 . The serum total bilirubin level &lt; 2 mg/dl . The prothrombin time &lt; 3 sec normal control . The platelet &gt; 7.5 x 104 / mm3 . The WBC &gt; 3,000 / mm3 . 7 . Patient must serum creatinine &lt; 1.5 mg/dl 8 . Cardiac function NYHA classification &lt; Grade II 9 . HBsAg ( + ) . 10 . Signed informed consent . 1 . Patients noncurative resection eligible . 2 . Resected HCCs histologically positive margin eligible . 3 . HCCs radiological evidence portal vein thrombus eligible . 4 . Patients systemic disease require concurrent usage glucoticosteroid immunosuppressant agent ( ) eligible . 5 . Patients advanced second primary malignancy eligible . 6 . Patients pregnancy breastfeed eligible . 7 . Patients severe cardiopulmonary disease eligible . 8 . Patients clinically significant psychiatric disorder eligible . 9 . Patients antineoplastic chemotherapeutic immunotherapeutic drug corticosteroid within 6 week commence protocol eligible . 10 . Patients prior lamividine and/or adefovir dipivoxil therapy eligible . 11 . AntiHCV positive patient eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Post-operative Hepatocellular Carcinoma .</keyword>
</DOC>